Spinal Cord Research Help
AboutCategoriesLatest ResearchContact
Subscribe
Spinal Cord Research Help

Making Spinal Cord Injury (SCI) Research Accessible to Everyone. Simplified summaries of the latest research, designed for patients, caregivers and anybody who's interested.

Quick Links

  • Home
  • About
  • Categories
  • Latest Research
  • Disclaimer

Contact

  • Contact Us
© 2025 Spinal Cord Research Help

All rights reserved.

  1. Home
  2. Research
  3. Pharmacology
  4. Resolution of chronic migraine headaches with intrathecal ziconotide: a case report

Resolution of chronic migraine headaches with intrathecal ziconotide: a case report

Journal of Pain Research, 2015 · DOI: http://dx.doi.org/10.2147/JPR.S84771 · Published: September 8, 2015

PharmacologyNeurologyPain Management

Simple Explanation

Migraine headaches are a common problem, especially for women, and can make it hard to work or enjoy family life. Regular treatments don't always work well for chronic migraine. Ziconotide is a drug that can help with severe pain, and this case report looks at whether it can help with migraines. A woman with multiple sclerosis, spasticity, leg pain, and severe migraines was treated with ziconotide via an intrathecal pump. She had previously tried many migraine treatments without much success. After starting ziconotide, the patient's leg pain improved and her migraines completely stopped for 8 months. This is the first reported case of ziconotide helping with migraines, suggesting it could be a new treatment option.

Study Duration
8 Months
Participants
One 59-year-old female
Evidence Level
Level 4, Case Report

Key Findings

  • 1
    The patient experienced complete resolution of migraine headaches following the initiation of low-dose intrathecal ziconotide (1 µg/day).
  • 2
    Prior to ziconotide, the patient had 22 migraine headache days per month, which were reduced to 4 with Botox injections, but resolved completely with ziconotide.
  • 3
    The patient was able to discontinue the use of triptans and significantly reduce the use of NSAIDs after starting ziconotide treatment.

Research Summary

This case report describes a 59-year-old female with chronic migraines who experienced complete resolution of her headaches after starting low-dose intrathecal ziconotide. The patient had previously tried multiple migraine treatments, including Botox injections, with limited success. Ziconotide was initially added to her intrathecal pump to manage neuropathic pain, but unexpectedly led to the elimination of migraine headaches. This is the first reported case of migraine improvement with intrathecal ziconotide, suggesting it may be a potential treatment option for patients with refractory chronic migraines.

Practical Implications

New Treatment Avenue

Ziconotide could represent a new treatment option for chronic migraine sufferers who do not respond well to traditional therapies.

Further Research Needed

Further studies are needed to examine the effects of ziconotide on migraines and to determine the optimal dose, delivery method, and patient selection criteria.

Improved Quality of Life

Effective migraine treatment with ziconotide could lead to a marked improvement in daily functional impairment and health care utilization for chronic migraine sufferers.

Study Limitations

  • 1
    Single case report limits generalizability.
  • 2
    Incidental discovery of ziconotide's effect on migraines.
  • 3
    Questions remain regarding the mechanism of action and optimal dosing.

Your Feedback

Was this summary helpful?

Back to Pharmacology